Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19

• Published in: Advances in radiation oncology Vol. 5; no. 4; pp. 659 - 665
• Main Authors: Zaorsky, Nicholas G., Yu, James B., McBride, Sean M., Dess, Robert T., Jackson, William C., Mahal, Brandon A., Chen, Ronald, Choudhury, Ananya, Henry, Ann, Syndikus, Isabel, Mitin, Timur, Tree, Alison, Kishan, Amar U., Spratt, Daniel E.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2020; Elsevier
• ISSN: 2452-1094; 2452-1094
• DOI: 10.1016/j.adro.2020.03.010

During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiation therapy management decisions. Radiation oncologists from the United States and the United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage patients with prostate cancer during the COVID-19 pandemic. A RADS framework was created: remote visits, and avoidance, deferment, and shortening of radiation therapy was applied to determine appropriate approaches. Recommendations were provided by the National Comprehensive Cancer Network risk group regarding clinical node-positive, postprostatectomy, oligometastatic, and low-volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits of between 1 and 6 months were deemed safe based on stage of disease. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node-positive, recurrence postsurgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4 to 6 months as necessary. Ultrahypofractionation is preferred for localized, oligometastatic, and low-volume M1, and moderate hypofractionation is preferred for postprostatectomy and clinical node positive disease. Salvage is preferred to adjuvant radiation. Resources can be reduced for all identified stages of prostate cancer. The RADS (remote visits, and avoidance, deferment, and shortening of radiation therapy) framework can be applied to other disease sites to help with decision making in a global pandemic.